The benefit of population-based studies for older patients with acute myeloid leukemia

Haematologica

Volumn 97, Issue 12, 2012, Pages 1781-1782

  Bacher, Ulrike ^a   Haferlach, Torsten ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CLOFARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RISK; COMORBIDITY; DISEASE ASSOCIATION; DNA METHYLATION; EDITORIAL; HLA TYPING; HUMAN; INDUCTION CHEMOTHERAPY; OVERALL SURVIVAL; RISK ASSESSMENT;

FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE;

EID: 84870419196     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.080242     Document Type: Editorial

References (12)

1. Schoch C, Kern W, Krawitz P, Dugas M, Schnittger S, Haferlach T, et al. Dependence of age-specific incidence of acute myeloid leukemia on karyotype. Blood. 2001;98(12):3500.
2. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481-5.
3. Mendler JH, Maharry K, Radmacher MD, Mrozek K, Becker H, Metzeler KH, et al. RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures. J Clin Oncol. 2012;30(25):3109-18.
4. Schiffer CA. I am older, not elderly, said the patient with acute myeloid leukemia. J Clin Oncol. 2010;28(4):521-3.
5. Oran B, and Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica 2012;97(12):1916-24.
6. Juliusson G, Billstrom R, Gruber A, Hellstrom-Lindberg E, Hoglunds M, Karlsson K, et al. Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival. Leukemia. 2006;20(1):42-7.
7. Pulsoni A, Pagano L, Latagliata R, Casini M, Cerri R, Crugnola M, et al. Survival of elderly patients with acute myeloid leukemia. Haematologica. 2004;89(3):296-302.
8. Krug U, Rollig C, Koschmieder A, Heinecke A, Sauerland MC, Schaich M, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet. 2010;376(9757):2000-8.
9. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4):562-9.
10. Niederwieser D, Lange T, Cross M, Basara N, Al-Ali H. Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML. Best Pract Res Clin Haematol. 2006;19(4):825-38.
11. Lübbert M, Bertz H, Ruter B, Marks R, Claus R, Wasch R, et al. Nonintensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transpl. 2009;44(9):585-8.
12. Juliusson G, Lazarevic V, Horstedt AS, Hagberg O, Hoglund M. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood. 2012;119(17):3890-9.